CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ProlastinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug3331 mRNA-1273 Wiki 0.71
drug2683 Standard Medical Treatment Wiki 0.58

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (Prolastin®) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19

The primary objective of the study is to determine if Prolastin plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 15 or who are dependent on invasive mechanical ventilation on Day 15 versus SMT alone in hospitalized participants with Coronavirus disease 2019 (COVID-19).

NCT04495101 COVID-19 Biological: Prolastin Drug: Standard Medical Treatment
MeSH:Coronavirus Infections

Primary Outcomes

Measure: Percentage of Participants Dying or Requiring ICU Admission

Time: Up to Day 15

Measure: Percentage of Participants Who are Dependent on Invasive Mechanical Ventilation

Time: Day 15

Secondary Outcomes

Measure: Change from Baseline in National Early Warning Score (NEWS)

Time: Day 1 through Day 29

Measure: Time to Clinical Response as Assessed by: NEWS ≤ 2 Maintained for 24 hours

Time: Day 1 through Day 29

Measure: Time to Hospital Discharge

Time: Day 1 through Day 29

Measure: Duration of ICU Stay

Time: Up to Day 29

Measure: Duration of Any Oxygen Use

Time: Day 1 through Day 29

Measure: Duration of Mechanical Ventilation

Time: Up to Day 29

Measure: Mean Change from Baseline in Ordinal Scale

Time: Day 1 through Day 29

Measure: Absolute Value Change from Baseline in Ordinal Scale

Time: Day 1 through Day 29

Measure: Percentage of Participants in Each Severity Category of the 7-Point Ordinal Scale

Time: Day 15, Day 29

Measure: Time to Sustained Normalization of Temperature

Time: Day 1 through Day 29

Measure: Percentage of Participants who Sustained Normalization of Temperature

Time: Day 1 through Day 29

Measure: Number of Participants who Develop Acute Respiratory Distress Syndrome (ARDS)

Time: Up to Day 29

Measure: Length of Time to Clinical Progression

Time: Up to Day 29

Measure: Mortality Through Day 29

Time: Up to Day 29

No related HPO nodes (Using clinical trials)